Betulin-related esters from birch bark tar: Identification, origin and archaeological significance

Birch bark tar, an organic material frequently encountered during archaeological excavations, has been identified from its lipid composition on the cracks of a ceramic dated to the late Neolithic. Lipids of this black substance were dominated by a characteristic triterpenoid assemblage of lupane-related triterpenoids from birch bark together with their thermal degradation products formed during preparation of the tar. Among the latter, four main series of unusual triterpenoid esters have been detected and were postulated to correspond to esters of Delta2-betulin and Delta2-dihydrobetulin based on their mass spectra and hydrolysis experiments. Their conclusive identification has been achieved by synthesis of reference compounds. These compounds most likely originate from the esterification between triterpenoid alcohols related to betulin and fatty acids from suberin formed upon heating of birch bark tar. They could be considered as markers of intense heating during birch bark tar preparation using the “single pot“ procedure

[Extraskeletal Osteosarcoma As An Obstructive Tumor of the Left Atrium - a Case-report]

The observed a fatal case of cardiac tumor obstructing the left atrium. Death occurred after massive hemoptysis. At autopsy, the histological diagnosis was primary cardiac osteosarcoma with metastases in the adrenal gland

Repairing the broken pots of the Late Neolithic in the South of France (3500-2300 BC). New data at the cross of functional and analytical approaches

International audienc

Tamoxifen and ovarian function.

BACKGROUND: Some studies suggest that the clinical parameter "amenorrhea" is insufficient to define the menopausal status of women treated with chemotherapy or tamoxifen. In this study, we investigated and compared the ovarian function defined either by clinical or biological parameters in pre-menopausal breast cancer patients treated with tamoxifen administered as adjuvant therapy. MATERIALS AND METHODS: Between 1999 and 2003, 138 premenopausal patients consecutively treated for early breast cancer were included. Sixty-eight received tamoxifen in monotherapy as the only adjuvant systemic treatment (Group I) and 70 were treated with tamoxifen after adjuvant chemotherapy (Group II). All patients had a confirmed premenopausal status based on clinical parameters and hormonal values at study entry. They were followed prospectively every 3 months for 3 years: menses data, physical examination and blood tests (LH, FSH, 17-beta-estradiol). Vaginal ultrasonography was carried out every 6 months. After 3 years, prospective evaluation was completed and monitoring of ovarian function was performed as usual in our institution (1x/year). All data were retrospectively evaluated in 2011. RESULTS: Three patients were excluded from the study in group I and 2 were excluded in group II. Patients were divided into 4 subgroups according to clinical data, i.e. menses patterns. These patterns were assessed by questionnaires. a: Regular menses (>10 cycles/year) b: Oligomenorrhea (5 to 9 cycles/year) c: Severe oligomenorrhea (1 to 4 cycles/year) d: Complete amenorrhea Estrogen levels did not appear to have any impact on disease-free survival rates after 3 or 8 years. FSH values were also documented and analyzed. They exhibited the same profile as estradiol values. CONCLUSIONS: Amenorrhea is an insufficient parameter to define menopausal status in patients receiving tamoxifen. Low estradiol levels must be coupled with other biological parameters to characterize endocrine status. These data are very important for the choice of endocrine therapy

Disease-free survival and overall survival in group I and group II.

<p>Disease-free survival and overall survival in group I and group II.</p

Disease-free survival according to 17-beta-estradiol level.

<p>Disease-free survival according to 17-beta-estradiol level.</p

Median FSH level.

<p>Median FSH level.</p

Menses patterns.

<p>Menses patterns.</p